- Report
- September 2023
- 65 Pages
Global
From €6752EUR$6,995USD£5,791GBP
- Report
- May 2022
- 330 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- August 2022
- 30 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- January 2019
- 40 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- July 2020
- 1740 Pages
Global
From €4633EUR$4,800USD£3,974GBP
- Report
- January 2019
- 35 Pages
Global
From €965EUR$1,000USD£828GBP
Gazyva is a type of drug used to treat certain types of leukemia, a type of cancer of the blood and bone marrow. It is a monoclonal antibody, which means it is designed to target and destroy cancer cells. Gazyva works by blocking a protein called CD20, which is found on the surface of certain types of leukemia cells. By blocking this protein, Gazyva prevents the cancer cells from growing and dividing.
Gazyva is approved for use in combination with chemotherapy to treat chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). It is also approved for use in combination with bendamustine to treat CLL.
Gazyva is manufactured by Roche, a Swiss pharmaceutical company. Other companies in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, and Novartis. Show Less Read more
